These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 8737134

  • 1. Safety profile of sparfloxacin in the treatment of respiratory tract infections.
    Rubinstein E.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():145-60. PubMed ID: 8737134
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies.
    Aubier M, Lode H, Gialdroni-Grassi G, Huchon G, Hosie J, Legakis N, Regamey C, Segev S, Vester R, Wijnands WJ, Tolstuchow N.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():73-82. PubMed ID: 8737127
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.
    Henry D, Ellison W, Sullivan J, Mansfield DL, Magner DJ, Dorr MB, Talbot GH.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2262-6. PubMed ID: 9736546
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
    Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L.
    Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
    O'Doherty B, Dutchman DA, Pettit R, Maroli A.
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sparfloxacin: potential clinical and economic impact in the treatment of respiratory infections.
    Stein GE, Havlichek DH.
    Pharmacotherapy; 1997 Dec; 17(6):1139-47. PubMed ID: 9399598
    [Abstract] [Full Text] [Related]

  • 16. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.
    Jaillon P, Morganroth J, Brumpt I, Talbot G.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():161-7. PubMed ID: 8737135
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men.
    Phillips I, Dimian C, Barlow D, Moi H, Stolz E, Weidner W, Perea E.
    J Antimicrob Chemother; 1996 May; 37 Suppl A():123-34. PubMed ID: 8737132
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.